Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
The latest analyst update on Anika Therapeutics centers on a higher price target, with modeled fair value moving from US$16 to US$21 per share. Research commentary describes this shift as a reflection of greater confidence in the company's ability to sustain profitability, supported by the recent Q2 beat, stronger margins, and raised guidance. As you read on, you will see how this evolving narrative is taking shape and what to watch to stay in step with it.
Stay updated as the Fair Value for Anika Therapeutics shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Anika Therapeutics.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
B. Riley lifted its modeled fair value for Anika Therapeutics to US$21 per share from US$18 after a Q2 beat, citing improved margins and guidance as support for a more constructive earnings profile.
-
Barrington also raised its price target on Anika Therapeutics to US$21 from US$17 following the Q2 report and a higher 2026 outlook, and highlighted strong international momentum as a contributor to the company's revenue mix.
-
Both firms pointed to OEM strength and commercial growth as key drivers that could help Anika keep profitability on a firmer footing, supported by structural cost improvements.
🐻 Bearish Takeaways
-
B. Riley flagged regulatory timing risks around Hyalofast, which could affect how quickly certain product contributions appear in reported results and may introduce some uncertainty into execution.
-
With both B. Riley and Barrington now aligned at US$21 per share, investors may want to watch how actual margins, international performance, and regulatory updates compare with these higher expectations.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
How This Changes the Fair Value For Anika Therapeutics
-
Fair value estimate for Anika Therapeutics has moved from US$16.0 to US$21.0 per share, an increase of about 31%.
-
Revenue growth assumption has shifted from 3.46% to 5.07% in the updated model.
-
Net profit margin assumption has moved from 16.03% to 11.25% for future periods.
-
Future P/E multiple has adjusted from 15.00x to 16.47x on projected earnings.
-
Discount rate has moved slightly from 7.3297% to 7.2911% in the valuation framework.
Never Miss an Update: Follow The Narrative
Narratives connect Anika Therapeutics' business story to a set of explicit forecasts and a fair value framework. They refresh when new earnings, guidance, or regulatory news comes in so you can see how the story is evolving in real time.
Head over to the Simply Wall St Community and follow the Narrative on Anika Therapeutics to stay up to date on:
-
How aging yet active populations and rising demand for joint preservation support the adoption of Integrity and Hyalofast in higher margin regenerative products.
-
The role of potential U.S. launches for Hyalofast and Cingal, manufacturing investments in Massachusetts, and cost controls in supporting the company's earnings profile.
-
Key risks such as OEM pricing pressure on Monovisc and Orthovisc, uncertainty around Hyalofast's U.S. regulatory outcome, and operational dependence on a single manufacturing facility.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ANIK .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
